Navigation Links
First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals' GGTI-2418
Date:5/1/2009

atements regarding the mechanism of action of GGTI-2418, its potential advantages, its potential for use in treating cancer, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning GGTI-2418. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of GGTI-2418, our ability to finance our development of GGTI-2418, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... OAKLAND, Calif., September 22, 2014 Patients who were treated ... a hemorrhagic stroke were significantly more likely to survive ... published today in JAMA Neurology . This study ... that the use of cholesterol-lowering statins can improve survival ... by a constriction or obstruction of a blood vessel ...
(Date:9/22/2014)... 22, 2014 Research and ... of the "Global Biotechnology Reagents Market 2014-2018" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Biotechnology reagents are chemical ... system to detect and examine another substance to ... in laboratories to prepare, collect, and examine specimens ...
(Date:9/22/2014)... of circulating tumor cells (CTCs) in a mouse model ... in several groups of CTCs, including significant differences from ... to generate metastases. In their study reported in ... investigators from the Massachusetts General Hospital (MGH) Cancer Center ... unexpected factors that may prove to be targets for ...
(Date:9/22/2014)... way to create a highly sensitive chemical sensor based ... have unique electronic properties that the researchers were able ... by 300 times. , The study is available online ... , Amin Salehi- Khojin, asst professor of mechanical and ... student and Bijandra Kumar, post doc where they are ...
Breaking Biology Technology:Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3Massachusetts General study reveals gene expression patterns in pancreatic CTCs 2Massachusetts General study reveals gene expression patterns in pancreatic CTCs 3Graphene imperfections key to creating hypersensitive 'electronic nose' 2
... KENILWORTH and WHITEHOUSE STATION, N.J., April 25 ,Schering-Plough/MERCK ... letter from the U.S. Food and Drug Administration,(FDA) ... montelukast for,the treatment of allergic rhinitis symptoms in ... New Drug Application filing for loratadine/montelukast was accepted,by ...
... Biopharmaceuticals,Inc. (Nasdaq: KERX ) announced today that it ... that the Company is not in,compliance with the $1.00 ... Global Market pursuant to Marketplace Rule 4450,(a)(5). This notification, ... is a standard communication when the bid price of ...
... Inverness Medical,Innovations, Inc. (Amex: IMA ), a ... the consumer and professional markets, announced,today that it ... Conference being held April 30 - May 2, ... Zwanziger, Chief Executive Officer, will,attend. His presentation is ...
Cached Biology Technology:Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast 2Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast 3Keryx Biopharmaceuticals Receives Nasdaq Notification 2Keryx Biopharmaceuticals Receives Nasdaq Notification 3
(Date:9/23/2014)... Company has secured $21 million in a Series C ... the Company,s cancer immunotherapy pipeline and advance its lead ... the round, with participation from Majuven and all existing ... Harbinger Venture Capital. , Eureka is engaged in ... mimic the functions of a T cell receptor, a ...
(Date:9/23/2014)... of scientists has identified a gene mutation that ... which the bone marrow fails to produce normal ... which three generations had blood disorders, the researchers ... telomeres, chromosomal structures with crucial roles in normal ... help suggest future molecular-based treatments that bypass the ...
(Date:9/23/2014)... the development of animals and plants. The central problem ... translated in a reliable manner to give specific spatial ... of stripe formation is a classic paradigm in developmental ... the French flag, is caused by a gradient of ... low concentrations of the morphogen a "blue", "white" or ...
Breaking Biology News(10 mins):Gene mutation discovered in blood disorder 2Recreating the stripe patterns found in animals by engineering synthetic gene networks 2
... the cacao genome is complete, a consortium of academic, ... scientists performed much of the sequencing work, which is ... website of the Cacao Genome Database project. Despite ... Inc., Cacao Genome Database scientists say one of their ...
... , BOSTON (9-15-10) -- A team led by Boston ... four-year grant from the National Institutes of Health to ... could lead to individual genome sequencing for less than ... on an initial, $2.2 million NIH grant and led ...
... 15 September 2010 -- The European Society for Medical Oncology ... the advancement of medical research. The awards will be presented ... 35th ESMO Congress, to take place from 8-12 October in ... the 2010 ESMO Award for his key role in the ...
Cached Biology News:Chocolate farmers could benefit from newly sequenced cacao genome 2Chocolate farmers could benefit from newly sequenced cacao genome 3Chocolate farmers could benefit from newly sequenced cacao genome 4BU team wins $4.1M genome grant 2Top cancer specialists receive ESMO awards 2Top cancer specialists receive ESMO awards 3Top cancer specialists receive ESMO awards 4
Sheep polyclonal to Streptomycin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule: Streptomycin conjugated to BSA....
Rabbit polyclonal to MAL ( Abpromise for all tested applications). entrezGeneID: 4118 SwissProtID: P21145...
Glutamate Receptor 5/1a...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Biology Products: